TOKYO, Jul 06 (Pulse News Wire) – ADR120S,Inc. (3750.T) announced that its subsidiary, ADR Therapeutics Co., Ltd., has made significant progress toward securing insurance coverage for its medical device, Celation Cell Therapy Kit SUI, used in treating male abdominal pressure urinary incontinence.
Following a review by the Insurance Application Committee held in June 2026, the product has advanced to the next stage of evaluation by the Central Social Health Insurance Council's Specialized Organization for Medical Materials (Shohozenshitsu). This advancement marks a crucial step towards obtaining insurance approval for the device, which utilizes autologous adipose-derived regenerative (stem) cells (ADRCs). The company continues to work diligently on further regulatory processes through Shohozenshitsu to achieve insurance coverage.
ADR120S,Inc. emphasizes its commitment to promoting regenerative medicine technologies and providing patients with innovative treatment options. Regarding potential impacts on the fiscal year ending March 2027, ADR120S,Inc.
Stated that it is currently assessing the situation and will promptly disclose any necessary updates.
🟢 Confidence: High AI-translated content.